small cell lung cancer

News

Mixed data from lung cancer trials on show at WCLC

Highlights of the WCLC show include new data for AstraZeneca's Tagrisso, Summit's ivonescimab, MSD/Daiichi's I-DXd, and BMS/Systimmune's iza-bren.

News

ASCO 25: Jazz, PharmaMar reveal SCLC survival data

Jazz and PharmaMar have revealed the overall survival data with their small-cell lung cancer drug Zepzelca, described as a 'milestone' in the disease.

News

Roche licenses Innovent ADC that could challenge Amgen drug

Roche licenses rights to a DLL3-targeted ADC from China's Innovent, hoping to bring a competitor to Amgen's lung cancer therapy Imdelltra to market.

News

FDA clears AZ's Imfinzi for aggressive lung cancer

AstraZeneca's Imfinzi becomes the first cancer immunotherapy to be FDA-approved for limited-stage small cell lung cancer (LS-SCLC).

Oncology

Inside ESMO 2024: Treatments, trials, and top HCPs on social...

Discover the latest treatments, clinical trials, and top healthcare professionals sharing insights on social media from the ESMO 2024 conference.

News

WCLC: MSD/Daiichi build case for phase 3 ADC for lung cancer

MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-st

Mixed data from lung cancer trials on show at WCLC

ASCO 25: Jazz, PharmaMar reveal SCLC survival data

Roche licenses Innovent ADC that could challenge Amgen drug

FDA clears AZ's Imfinzi for aggressive lung cancer

Inside ESMO 2024: Treatments, trials, and top HCPs on social...

WCLC: MSD/Daiichi build case for phase 3 ADC for lung cancer

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

small cell lung cancer

Editor's Picks